- Home
- ADSE vs MLYS Comparison
ADSE vs MLYS Comparison
Compare ADSE & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- MLYS
- Stock Information
- Founded
- ADSE 1980
- MLYS 2019
- Country
- ADSE Ireland
- MLYS United States
- Employees
- ADSE N/A
- MLYS N/A
- Industry
- ADSE Industrial Specialties
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- ADSE Consumer Discretionary
- MLYS Health Care
- Exchange
- ADSE Nasdaq
- MLYS Nasdaq
- Market Cap
- ADSE 777.7M
- MLYS 893.0M
- IPO Year
- ADSE N/A
- MLYS 2023
- Fundamental
- Price
- ADSE $13.43
- MLYS $14.87
- Analyst Decision
- ADSE Hold
- MLYS Strong Buy
- Analyst Count
- ADSE 1
- MLYS 3
- Target Price
- ADSE $14.00
- MLYS $33.00
- AVG Volume (30 Days)
- ADSE 65.8K
- MLYS 679.3K
- Earning Date
- ADSE 05-16-2025
- MLYS 05-12-2025
- Dividend Yield
- ADSE N/A
- MLYS N/A
- EPS Growth
- ADSE N/A
- MLYS N/A
- EPS
- ADSE N/A
- MLYS N/A
- Revenue
- ADSE $158,974,606.00
- MLYS N/A
- Revenue This Year
- ADSE $107.27
- MLYS N/A
- Revenue Next Year
- ADSE $57.96
- MLYS N/A
- P/E Ratio
- ADSE N/A
- MLYS N/A
- Revenue Growth
- ADSE 168.42
- MLYS N/A
- 52 Week Low
- ADSE $10.17
- MLYS $8.24
- 52 Week High
- ADSE $16.35
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- ADSE 50.33
- MLYS 61.10
- Support Level
- ADSE $13.02
- MLYS $14.03
- Resistance Level
- ADSE $13.65
- MLYS $15.79
- Average True Range (ATR)
- ADSE 0.70
- MLYS 0.93
- MACD
- ADSE 0.08
- MLYS 0.16
- Stochastic Oscillator
- ADSE 65.00
- MLYS 92.27
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services which enable the customer to control and manage the system. Geographically, it derives a majority of its revenue from Europe.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.